Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganciclovir-Cidofovir CMV Retinitis Trial
NCT00000143Phase 3Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- May 1997
- Primary completion
- Jun 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cidofovir in cytomegalovirus retinitis (2 arms), sponsored by Johns Hopkins Bloomberg School of Public Health. Primary endpoint: Overall Survival at 3 years. Started May 1997; status: completed.
02
Drugs
cidofovir
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT00000143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000143.